Printer Friendly

Brammer Bio Launches Gene Therapy Product Manufacturing Operations in Massachusetts.

M2 PHARMA-November 29, 2017-Brammer Bio Launches Gene Therapy Product Manufacturing Operations in Massachusetts

(C)2017 M2 COMMUNICATIONS

- US-based cell and gene therapy contract development and manufacturing organisation Brammer Bio has completed renovations and launched its late-stage clinical capacity and commercial-ready cGMP manufacturing site in Cambridge, Massachusettsfor gene therapy products, the company said.

According to Brammer Bio, the 66,000 square-foot Cambridge facility in the heart of Kendall Square was previously licensed by regulatory authorities to manufacture four commercial protein therapeutic products.

The facility houses equipment in cleanroom suites specially designed to accommodate a broad-range of gene therapy manufacturing process technologies.

In January 2017, Brammer acquired the Cambridge site from Biogen and on-boarded an experienced team of 100 employees that has expanded to a team of 150.

Currently, the facility includes multiple drug substance suites able to support large-scale adherent and stirred tank production, an automated fill/finish system leveraging isolator technology, quality control laboratories, and process development space.

The facility is designed with HVAC system for grade C clean rooms, unidirectional flow, and a centralized vaporised hydrogen peroxide system to ensure suite sanitisation.

The site's launch demonstrates Brammer's end-to-end CDMO services from early phase process development through commercial manufacturing.

The company also acquired a 49,000 square-foot GMP distribution center in Somerville, Massachusetts, providing high-quality storage and clinical and commercial distribution capabilities.

In September of this year, Brammer announced the completion of a doubling of its early phase clinical manufacturing capacity in Alachua, Florida.

The Brammer team consists of over 300 extraordinary employees focused exclusively on serving the cell and gene therapy needs of its clients and their patients.

Brammer Bio provides clinical and commercial supply of vectors for in vivo gene therapy and ex vivo modified-cell based therapy, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. Brammer is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders and all employees.

Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector.

Over the past two decades, Ampersand has managed more than USD 1bn in private equity partnerships.

Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUUK
Date:Nov 29, 2017
Words:404
Previous Article:Genetic Predisposition to Later Puberty Causes Lower Bone Density in Children and Adults, Study Finds.
Next Article:DaVita Medical Group acquires NPN & IPA network in the Pacific Northwest.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters